Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) was founded on November 5, 2010. It is headquartered in Montreal, Quebec, Canada. It has 30 full-time employees. It is a clinical-stage biopharmaceutical company. To meet the medical needs of patients with diseases, develop treatments to improve their diseases.
April 2019, Ipsen (Ipsen) for $ 1.04 billion acquisition of Clementia Pharmaceuticals, the equivalent of $ 25 per share.
Clementia Pharmaceuticals (CMTA):
Clementia Pharmaceuticals’ main product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (RAR gamma agonist), and is used in various tissues in animal models. Shows effective prevention of abnormal new bone formation and scar tissue formation (or fibrosis) activity.
Clementia Pharmaceuticals is currently developing palovarotene for the treatment of Fibrodysplasia Ostificans Progressiva (FOP) and multiple osteochondroma (MO), which are in phase III and phase II/III clinical trials respectively. The company believes that if the product is approved for FOP or MO treatment, palorotene can become the standard of care for these indications.
Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) submitted its IPO prospectus on 6/30/2017 and plans to IPO on NASDAQ on 8/2/2017. The issue price is US$15.00, 7.15 million shares are issued, and US$123.3 million is raised. Stock code: CMTA.